DALLAS, Oct. 31 Access Pharmaceuticals, Inc.(OTC Bulletin Board: ACCP) announced today that it will make a presentation atthe Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference to be heldNovember 5-7, 2007 at the New York Palace Hotel in New York City. Stephen R.Seiler, President and CEO of Access is scheduled to speak on Tuesday, November6, 2007 at 10:35 am Eastern time and will give a corporate overview anddiscuss the Company's product opportunities.
The presentation will be available via a webcast and can be accessed at:http://www.wsw.com/webcast/rrshq12/accp.ob. The replay can be obtained at thesame link for up to 90 days after the live presentation.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company thatdevelops and commercializes propriety products for the treatment andsupportive care of cancer patients. Access' products include ProLindac(TM),currently in Phase II clinical testing of patients with ovarian cancer andMuGard(TM) for the management of patients with mucositis. The company also hasother advanced drug delivery technologies including Cobalamin(TM)-mediatedtargeted delivery and oral drug delivery. Access has announced the executionof a definitive merger agreement to acquire Somanta. The acquisition ofSomanta has not yet closed and the closing is subject to numerous closingconditions. For additional information on Access Pharmaceuticals, please visitour website at http://www.accesspharma.com.
This press release contains certain statements that are forward-lookingwithin the meaning of Section 27a of the Securities Act of 1933, as amended,and that involve risks and uncertainties. These statements include thoserelating to: Access' plans to initiate clinical trials, the value of itsproducts in the market, its ability to achieve clinical and commercialsuccess, its ability to successfully develop marketed products and the abilityto obtain or meet the closing conditions in the merger agreement with SomantaPharmaceuticals, Inc. and applicable regulatory and tax requirements, and tootherwise complete the merger in a timely manner, yet there can be noassurances that the closing conditions will be met or waived or that thetransaction will close. These statements are subject to numerous risks,including but not limited Access' need to obtain additional financing and tothe risks detailed in Access' and Somanta's Annual Reports on Form 10-KSB andother reports filed by Access and Somanta with the Securities and ExchangeCommission.
SOURCE Access Pharmaceuticals, Inc.